For research use only. Not for therapeutic Use.
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis.[1][2][3].
Ethamsylate (480 μM, 30 mim) prolongs lifetime of neutrophils[1].
Ethamsylate (0-100 μM, 3-8 h) inhibits migration and tubulogenesis on matrigel in endothelial cells[3].
Ethamsylate (0-100 μM, 48 h), inhibits the signaling of FGF/FGFR, decreases phosphorylation Levels of AKT and Erk1/2[3].
Ethamsylate (100 mg/kg, p.o., twice a day, three days) attenuates mutilated secondary pathogenesis and exhibits a neuroprotective role in mice of spinal cord injury[4].
| Catalog Number | A000561 |
| CAS Number | 2624-44-4 |
| Synonyms | 2,5-dihydroxybenzenesulfonic acid;N-ethylethanamine |
| Molecular Formula | C10H17NO5S |
| Purity | ≥95% |
| InChI | InChI=1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3 |
| InChIKey | HBGOLJKPSFNJSD-UHFFFAOYSA-N |
| SMILES | CCNCC.C1=CC(=C(C=C1O)S(=O)(=O)O)O |
| Reference | [1]. Zawrotniak M, et al. Selected mucolytic, anti-inflammatory and cardiovascular drugs change the ability of neutrophils to form extracellular traps (NETs). Acta Biochim Pol. 2015;62(3):465-73. [2]. Kovács L, et al. Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro. Experientia. 1981 Nov 15;37(11):1182-3. [3]. Albiñana V, et al. Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition). TH Open. 2019 Jul 26;3(3):e230-e243. [4]. Dolma S, et al. Ethamsylate Attenuates Mutilated Secondary Pathogenesis and Exhibits a Neuroprotective Role in Experimental Model of Spinal Cord Injury. Neuroscience. 2022 Feb 21;484:26-37. |
